Citadel Advisors
CMRAW

Citadel Advisors’s Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 CMRAW Stock Holding History

Citadel Advisors’s Portfolio CMRAW Stock Details CMRAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-38,401
Closed -$691 – 15633
2023
Q3 		$691 Buy
38,401
+15,632
+69% +$516 ﹤0.01% 14001
2023
Q2 		$676 Sell
22,769
-6,211
-21% -$207 ﹤0.01% 14066
2023
Q1 		$1.62K Buy
+28,980
New +$1.44K ﹤0.01% 14269

Other funds holding CMRAW

LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Citadel Advisors's CMRAW Position: Q4 2023 in Review

Citadel Advisors sold out of Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 (CMRAW) in Q4 2023, closing a stake of 38,401 shares — an estimated $691 sold.

Citadel Advisors first reported a position in CMRAW in Q1 2023 and held it in 3 quarters. The position peaked at $1.62K in Q1 2023. 3 funds tracked by Wall St. Rank hold CMRAW as of Q4 2023.

  • Citadel Advisors reported no remaining Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 38,401 Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 shares in Q4 2023, an estimated $691.
  • Citadel Advisors first reported a position in Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 in Q1 2023 and held it in 3 quarters.
  • Citadel Advisors's Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 position peaked at $1.62K in Q1 2023.
  • 3 funds tracked by Wall St. Rank held Comera Life Sciences Holdings, Inc. Warrant expiring 5/19/2027 as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.